ClinicalTrials.gg
RecruitingNCT07163338SAPLAGEUpdated Nov 25, 2025

Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)

An interventional study of Collectio nof blood in Antiphospholipid Syndrome, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by CHU de Reims · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Antiphospholipid Syndrome with a site in France — 11 open to participants now, 11 under way, 1 of them phase 3. Antiphospholipid Syndrome · France.

Planned enrollment
Largest of 14
400 · median 102
Started
2025
with 2 others
No phase
7 of 31
3 open now
Primary completion
2027-12
later than 3 of 10 live
Registered
27th of 31
by date
Lead sponsor
1 of 31
CHU de Reims

Among the 31 studies in Antiphospholipid Syndrome with a site in France, this one has the largest planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 27th registered.

Antiphospholipid Syndrome

121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.

Browse Antiphospholipid Syndrome studies →

Open to participants now

11 of the 31 studies in Antiphospholipid Syndrome with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 38 Antiphospholipid Syndrome studies recruiting now, 14 (37%) set no upper age limit and 19 (50%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Antiphospholipid Syndrome with a site in France, or all of them as a file.
02

Study summary

Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades. In individuals under the age of 65, the etiologies of ischemic stroke (IS) are diverse, and management is well-established. Antiphospholipid syndrome (APS) accounts for 10 to 20% of the causes of stroke in this population. In elderly individuals, APS is not systematically investigated due to the predominance of embolic, atherosclerotic, and small vessel disease causes. However, delayed discovery of APS is not uncommon and is more frequently associated with the occurrence of arterial thrombosis. Moreover, the management of APS involves several challenges given the risk of recurrence of thrombosis and the potential association with conventional cardiovascular risk factors. The antithrombotic treatment consists of lifelong anticoagulation, excluding direct oral anticoagulants (DOACs) due to the risk of thrombotic recurrence. The main objective of the study will be to assess the prevalence of antibodies useful for the diagnosis of APS (Sapporo criteria) in individuals aged 65 or older hospitalized for an ischemic stroke (IS) or transient ischemic attack (TIA).

Furthermore, the classification of APS is likely to evolve in the coming years with the inclusion of new clinically relevant antibodies (anti-phosphatidylserine and anti-phosphatidylethanolamine) because of their strong association with the occurrence of thrombosis. Even though they are often associated with circulating anticoagulants, they are also found in 10% of APS cases negative for other antibodies.

Patient inclusion in the study should occur during the acute phase of the stroke, before the initiation of anticoagulant treatment.

Thus, after verifying the inclusion and exclusion criteria, patients will be informed and must sign the informed consent form if they agree to participate.

After inclusion, the research procedure will be as follows:

  • Conduct a unique immunological biological assessment with:

    • Part performed as part of standard care: circulating anticoagulants, anti-cardiolipin antibodies, and anti-β2-glycoprotein type 1.
    • Part performed specifically for the study (3.5 mL of additional blood): anti-phosphatidylserine and anti-phosphatidylethanolamine antibodies. The search for these antibodies will be performed using the 7mL dry tube collected for anti-cardiolipin and anti-β2-glycoprotein type 1 antibody testing.
    • If the diagnostic sample is positive for any of these antibodies, a follow-up at 3 months is recommended and will be performed as part of standard care to confirm the APS diagnosis.
  • Data collection will include patient details, stroke/TIA details, biological data, and follow-up. As part of routine follow-up, patients will be seen in a neurological consultation at 6 months.

Clinical and biological data will be reviewed at the end of the study by two doctors (a neurologist and an internist) to confirm or exclude the APS diagnosis and its contribution to the neurological condition.

An internal medicine follow-up will be initiated for patients with confirmed APS, and an appropriate treatment will be proposed.

Read the detailed description

Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades, particularly in acute-phase management. In 80% of cases, stroke is ischemic (IS), and the etiology and prognosis can vary depending on the patient's age. A comprehensive etiological workup allows for the adaptation of secondary prevention, thereby helping to reduce the risk of recurrence.

In individuals under the age of 65, etiologies of ischemic stroke (IS) are multiple, and management is well-established. In individuals under 50, antiphospholipid syndrome (APS) accounts for 10 to 20% of the causes of ischemic stroke, highlighting the importance of this etiology in younger patients. The diagnosis of IS/TIA related to APS relies on expert evaluation of clinical and biological data.

This syndrome is characterized by thrombosis in arterial or venous territories as well as the detection of specific antibodies (anti-cardiolipin antibodies, and/or anti-β2-glycoprotein type 1 antibodies, and/or circulating anticoagulants), with a cumulative risk of thrombosis depending on the number of antibodies identified. Historically, APS was associated with lupus and considered secondary, but it is now well accepted that it can occur in isolation and thus be primary.

APS is not systematically sought in elderly patients due to the predominance of cardioembolic, atherosclerotic, and small vessel disease causes. However, the late discovery of APS is not uncommon and is more frequently associated with arterial thrombosis. A retrospective study including a systematic search for APS in patients with IS found a significant association between older age and the presence of antiphospholipid antibodies (71 vs 66 years). Management presents several challenges due to the risk of recurrence of both arterial and venous thrombosis, as well as the potential association with conventional cardiovascular risk factors. Antithrombotic treatment involves lifelong anticoagulation, excluding direct oral anticoagulants (DOACs) such as Rivaroxaban due to the risk of thrombotic recurrence. A retrospective study also showed an association between APS and atrial fibrillation, reaching 30%. Atrial fibrillation, the prevalence of which increases with age, is increasingly treated with DOACs, suggesting the need to investigate APS in order to adapt the antithrombotic treatment and reduce the risk of recurrence.

Furthermore, the classification of APS is likely to evolve in the coming years with the inclusion of new clinically relevant antibodies, such as anti-phosphatidylserine and anti-phosphatidylethanolamine. These antibodies are strongly associated with the occurrence of thrombosis. Moreover, although these antibodies are strongly associated with circulating anticoagulants (which are difficult to detect due to the need for no anticoagulant treatment at the time of sample collection), they are also found in 10% of APS cases that are negative for other antibodies. With this study, we propose to systematically investigate these two antibodies as well.

Patient inclusion in the study should occur during the acute phase of the stroke, before the initiation of anticoagulant treatment.

Thus, after verifying the inclusion and exclusion criteria:

  • If the patient's condition allows, the patient will be informed of the study's methods and objectives and must sign the informed consent form if they agree to participate.
  • If the patient's condition does not permit informing them or obtaining their consent, close relatives present will be informed about the study's objectives and methods and will be asked to sign the consent form if they agree to the patient's participation. The patient will be informed as soon as possible, and their consent will be requested for continued participation if needed.

After inclusion, the research procedure will be as follows:

  • Conduct a unique immunological biological assessment with:

    • Part performed as part of standard care: circulating anticoagulants, anti-cardiolipin antibodies, and anti-β2-glycoprotein type 1.
    • Part performed specifically for the study (3.5 mL of additional blood): anti-phosphatidylserine and anti-phosphatidylethanolamine antibodies. The search for these antibodies will be performed using the 7mL dry tube collected for anti-cardiolipin and anti-β2-glycoprotein type 1 antibody testing.
    • If the diagnostic sample is positive for any of these antibodies, a follow-up at 3 months is recommended and will be performed as part of standard care to confirm the APS diagnosis.
  • Data collection will include patient details (age, sex, etc.), stroke/TIA (location, etiology, etc.), biological data, and follow-up (recurrence, disability, and mortality during hospitalization and at 6 months). As part of routine follow-up, patients will be seen in a neurological consultation at 6 months.

Clinical and biological data will be reviewed at the end of the study by two doctors (a neurologist and an internist) to confirm or exclude the APS diagnosis and its contribution to the neurological condition.

An internal medicine follow-up will be initiated for patients with confirmed APS, and an appropriate treatment will be proposed.

03

Conditions studied

  • Antiphospholipid Syndrome

Keywords

  • Antiphospholipid syndrome
  • antiphospholipid antibody syndrome
  • stroke
  • ischemic stroke
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

inclusion criteria :

  • patients aged 65 and over during the inclusion phase
  • hospitalized for a /ischemic stroke in neurology or internal medicine department during the inclusion phase
  • affiliated with social security system exclusion criteria :
  • patients under 65 years old
  • under legal guardianship, curatorship, or tutorship
  • incarcerated
  • under psychiatric care
  • admitted to a healthcare or social institution
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Patients

    Other: Collectio nof blood

Interventions

  • OtherCollectio nof blood

    Collection of an additional volume of blood in the initial blood test.

06

What researchers measure

Primary outcomes

  1. Prevalence of antiphospholipid antibodies in patients aged at least 65 years hospitalized for a TIA or an ischemic stroke

    Evaluate the prevalence of antibodies useful for the diagnosis of Antiphospholipid syndrome in patients aged at least 65 years hospitalized for a TIA or a stroke : anticardiolipin antibodies, anti-beta-2-glycoprotein-I lantibodies and lupus anticoagulant

    Time frame: At the inclusion

Secondary outcomes

  1. Prevalence of confirmed Antiphospholipid syndrome at 12 weeks

    Prevalence of confirmed Antiphospholipid syndrome according to Sapporo criteria

    Time frame: At 12 weeks

  2. Type of TIA/stroke, location and clinical manifestations

    In cases of confirmed Antiphospholipid syndrome, describe the type of stroke/TIA, its location and its clinical manifestations

    Time frame: At the inclusion

  3. Prevalence of anti-phosphatidylethanolamine antibodies

    Prevalence of anti-phosphatidylethanolamine antibodies

    Time frame: At the inclusion

  4. Prevalence of anti-phosphatidylserine antibodies

    Prevalence of anti-phosphatidylserine antibodies

    Time frame: At the inclusion

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Sep 9, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Dec 16, 2027
CompletionEst.
Mar 16, 2028
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07163338
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Sep 9, 2025
Start date
Sep 16, 2025
Primary completion
Dec 16, 2027 (estimated)
Completion
Mar 16, 2028 (estimated)
Last update
Nov 25, 2025

Study contacts

Kévin DIDIER
Contact
kdidier@chu-reims.fr
03 26 83 24 44 ext. 0033
Solène MOULIN
Contact
smoulin@chu-reims.fr
03 26 78 92 99 ext. 0033

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion